Jason Kelly (biotechnologist)

Jason Kelly (biotechnologist)
Name	Jason Kelly
Nationality	American
Alma mater	Massachusetts Institute of Technology
Occupation	Biotechnologist; Entrepreneur
Known for	Founding Ginkgo Bioworks

Jason Kelly (biotechnologist) is an American entrepreneur and synthetic biology researcher known for co-founding Ginkgo Bioworks, a company that applies automated biology and organism engineering to industrial biotechnology. He has been involved in ventures and initiatives linking laboratory automation, computational design, and entrepreneurship across the Boston biotech ecosystem, with connections to academic institutions, venture capital firms, and incubators.

Early life and education

Kelly grew up in the United States and pursued undergraduate and graduate studies at the Massachusetts Institute of Technology, where he studied biotechnology-adjacent topics and participated in laboratories linked to synthetic biology. At MIT he interacted with faculty and students associated with the Broad Institute, Wyss Institute, and research groups led by figures connected to the development of CRISPR, directed evolution, and other modern biological engineering approaches. His academic formation placed him in networks overlapping with alumni who later worked at Genentech, Amgen, Novartis, Pfizer, and start-ups emerging from the Kendall Square innovation district.

Career and entrepreneurship

After MIT, Kelly co-founded Ginkgo Bioworks with colleagues from MIT, building a platform that combined laboratory automation, software, and biological design. Ginkgo positioned itself at the intersection of industrial biotechnology, partnering with companies in sectors such as Monsanto, Bayer, Cargill, BASF, and consumer brands that had previously contracted research with firms like Amyris and Zymo for fermentation and metabolic engineering. Kelly and co-founders engaged with investors from Y Combinator, Andreessen Horowitz, Flagship Pioneering, Sequoia Capital, and GV, and later navigated public markets with ties to NYSE processes and regulatory frameworks influenced by agencies like the Food and Drug Administration.

Under Kelly's leadership, Ginkgo expanded facilities and infrastructure resembling the automated foundries associated with industrialized approaches in companies such as Illumina and Thermo Fisher Scientific, while collaborating with academic labs at Harvard University, Stanford University, University of California, Berkeley, and the Wyss Institute. Ginkgo's commercial offerings targeted customers in agriculture supply chains, pharmaceutical development, chemical manufacturing, and consumer goods companies that had previously sourced biologics from contract research organizations like Charles River Laboratories and WuXi AppTec.

Research and innovations

Kelly has been associated with efforts to scale organism engineering through modular workflows that integrate laboratory robotics, high-throughput screening, and bioinformatics. The technical approach at Ginkgo mirrored advances seen in synthetic biology laboratories that used methods from pioneers linked to Addgene repositories, Stanley Cohen-style cloning traditions, and modern genome editing exemplified by Jennifer Doudna and Emmanuelle Charpentier work on CRISPR-Cas9. Innovations included platformizing strain engineering akin to protocols used at Amyris and Zymergen, and aiming to reduce cycle times for design-build-test-learn loops similar to automation trends at Beckman Coulter and Hamilton Company.

Kelly's projects intersected with computational biology themes cultivated by researchers at CSAIL, Broad Institute bioinformatics groups, and companies like DeepMind and Insitro that apply machine learning to biological design. Ginkgo's data-centric model echoed practices from Illumina sequencing pipelines and biofoundry initiatives found at institutions such as the National Institute of Standards and Technology and the European Bioinformatics Institute.

Y Combinator and biotechnology advocacy

Jason Kelly has maintained ties with Y Combinator and was part of a cohort that helped normalize accelerator engagement for life sciences startups historically absent from predominantly software-focused incubators. He contributed to dialogues linking accelerator models popularized by Paul Graham and Sam Altman with capital formation strategies from firms like Khosla Ventures and Third Rock Ventures that back biotech ventures. Kelly advocated for combining wet-lab infrastructure with investor networks common to Silicon Valley, encouraging crossovers with entities such as Andreessen Horowitz and policy forums where leaders from DARPA and the National Institutes of Health discuss biotechnology funding and preparedness.

Through public talks and panel appearances, Kelly engaged with audiences at venues including TechCrunch Disrupt, SXSW, Biotech Showcase, and conferences convened by BIO and MassBio, promoting themes of platformization, reproducibility, and responsible development that resonate with organizations like the National Academies of Sciences, Engineering, and Medicine and standards efforts from the Organisation for Economic Co-operation and Development.

Awards and recognition

Kelly and Ginkgo received attention from media outlets and industry awarders that spotlight entrepreneurial achievement in biotechnology, aligning with recognition previously given to founders in companies such as Moderna, Grail, Bluebird Bio, and Regeneron. Coverage in publications tied to the Wall Street Journal, New York Times, MIT Technology Review, and Forbes highlighted the company's growth, fundraising, and partnerships. Institutional acknowledgements and invitations placed Kelly among presenters at forums organized by World Economic Forum, TED, and events hosted by university entrepreneurship centers at MIT, Harvard Business School, and Stanford Graduate School of Business.

Category:American biotechnologists Category:Massachusetts Institute of Technology alumni